vimarsana.com
Home
Live Updates
Keymed Biosciences Announces 2023 Annual Results and Business Updates : vimarsana.com
Keymed Biosciences Announces 2023 Annual Results and Business Updates
Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA...
Related Keywords
Chengdu ,
Sichuan ,
China ,
United States ,
American ,
Bo Chen ,
Keymed Biosciences ,
Hong Kong Stock Exchange On ,
Astrazeneca ,
European Hematology Association ,
American Society Of Clinical Oncology ,
American Society Of Hematology ,
Prnewswire Keymed Biosciences Inc ,
Keymed Biosciences Inc ,
New Drug Application ,
Executive Director ,
Chief Executive Officer ,
American Society ,
Clinical Oncology ,
Hong Kong Stock Exchange ,
vimarsana.com © 2020. All Rights Reserved.